HeartSciences (HSCS) Investor presentation summary

Market opportunity and growth

• Addressing a $30 billion global ECG market projected by 2034, with over 100 million ECG tests annually in the US and up to 1 billion worldwide.

• AI-driven ECG solutions expected to drive approximately 150% market growth from 2024 to 2034.

• Recurring revenue model through SaaS software, device sales, and pay-per-use or subscription for algorithms.

• Medicare reimbursement for AI-ECG at $128 per test starting January 2025.

• Positioned as the only Nasdaq-listed AI-ECG company with a unique software platform and next-gen hardware.

Technology and product platform

• MyoVista Insights is a cloud-native ECG software platform compatible with existing hardware, requiring no new devices.

• Platform hosts both proprietary and third-party AI-ECG algorithms, creating a marketplace for clinical applications.

• MyoVista wavECG device designed for portability and ease of use in frontline healthcare.

• Software platform offers best-in-class usability, interoperability, and cybersecurity.

• AI-ECG algorithms significantly expand ECG's clinical value, enabling earlier detection of a broad range of heart diseases.

Regulatory and reimbursement milestones

• MyoVista Insights software does not require FDA clearance and is rolling out to early adopters.

• AI-ECG algorithms and MyoVista wavECG device are targeting FDA 510(k) clearance as Class II products, with submissions planned for 2026.

• New FDA classification for cardiovascular machine learning-based software established in late 2023.

• New CPT codes for AI-ECG introduced in 2023, with CMS reimbursement effective from January 2025.